Cargando…

Corrigendum: CREB5 hypermethylation involved in the ganglioside GM1 therapy of Parkinson's disease

Detalles Bibliográficos
Autores principales:	Wang, Rui, Tong, Shanshan, Wang, Mengdi, Zou, Junjie, Wang, Nan, Sun, Fengjiao, Zhou, Xiaosheng, Chen, Jinbo, Wang, Hongcai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Aging Neuroscience
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10434278/ https://www.ncbi.nlm.nih.gov/pubmed/37600516 http://dx.doi.org/10.3389/fnagi.2023.1250440

Ejemplares similares

CREB5 hypermethylation involved in the ganglioside GM1 therapy of Parkinson’s disease
por: Wang, Rui, et al.
Publicado: (2023)

The Key Role of GM1 Ganglioside in Parkinson’s Disease
por: Chowdhury, Suman, et al.
Publicado: (2022)

Pathophysiology of Ganglioside GM1 in Ischemic Stroke: Ganglioside GM1: A Critical Review
por: Zhang, Wenchao, et al.
Publicado: (2019)

The relationship between depletion of brain GM1 ganglioside and Parkinson's disease
por: Sonnino, Sandro
Publicado: (2023)

Antidepressant-Like Effects of GM1 Ganglioside Involving the BDNF Signaling Cascade in Mice
por: Jiang, Bo, et al.
Publicado: (2016)

Physiopathological function of hematoside (GM3 ganglioside)
por: INOKUCHI, Jin-ichi
Publicado: (2011)

Secondary ganglioside GM2 accumulation in mucopolysaccharidoses
por: Sandhoff, Konrad
Publicado: (2021)

Ganglioside GM1 and the Central Nervous System
por: Guo, Zhongwu
Publicado: (2023)

The cytoprotective role of GM1 ganglioside in Huntington disease cells
por: Hart, Hannah S., et al.
Publicado: (2022)

Anti-inflammatory role of GM1 and other gangliosides on microglia
por: Galleguillos, Danny, et al.
Publicado: (2022)

Systemic deficiency of GM1 ganglioside in Parkinson’s disease tissues and its relation to the disease etiology
por: Ledeen, Robert, et al.
Publicado: (2022)

Ganglioside GM3 Is Antiangiogenic in Malignant Brain Cancer
por: Seyfried, Thomas N., et al.
Publicado: (2010)

GM1 ganglioside-independent intoxication by Cholera toxin
por: Cervin, Jakob, et al.
Publicado: (2018)

Ganglioside GM2: a potential biomarker for cholangiocarcinoma
por: Talabnin, Krajang, et al.
Publicado: (2020)

Turning the spotlight on the oligosaccharide chain of GM1 ganglioside
por: Chiricozzi, Elena, et al.
Publicado: (2021)

Biochemical Correction of GM2 Ganglioside Accumulation in AB-Variant GM2 Gangliosidosis
por: Deschenes, Natalie M., et al.
Publicado: (2023)

Sialidase NEU3 action on GM1 ganglioside is neuroprotective in GM1 gangliosidosis
por: Allende, Maria L., et al.
Publicado: (2023)

Protection against Experimental Stroke by Ganglioside GM1 Is Associated with the Inhibition of Autophagy
por: Li, Li, et al.
Publicado: (2016)

Preparation of Ganglioside GM1 by Supercritical CO(2) Extraction and Immobilized Sialidase
por: Ji, Li, et al.
Publicado: (2019)

Corrigendum: Diagnostic value of striatal (18)F-FP-DTBZ PET in Parkinson's disease
por: Liu, Xiu-Lin, et al.
Publicado: (2022)

Corrigendum: A progression analysis of motor features in Parkinson's disease based on the mapper algorithm
por: Ma, Ling-Yan, et al.
Publicado: (2023)

Clinical Heterogeneity of Anti-GM2-Ganglioside-Antibody Syndrome
por: Kim, Jong Kuk, et al.
Publicado: (2018)

Modified Iron Deposition in Nigrosomes by Pharmacotherapy for the Management of Parkinson’s Disease
por: Wang, Mengdi, et al.
Publicado: (2022)

Enhanced Susceptibility to Chemoconvulsant-Induced Seizures in Ganglioside GM3 Synthase Knockout Mice
por: Tang, Fu-Lei, et al.
Publicado: (2020)

Machine Learning Models for Diagnosis of Parkinson’s Disease Using Multiple Structural Magnetic Resonance Imaging Features
por: Ya, Yang, et al.
Publicado: (2022)

Corrigendum: Experimental Models of Cognitive Impairment for Use in Parkinson's Disease Research: The Distance Between Reality and Ideal
por: Fan, Yaohua, et al.
Publicado: (2021)

Neuromelanin magnetic resonance imaging of substantia nigra and locus coeruleus in Parkinson’s disease with freezing of gait
por: Wang, Shangpei, et al.
Publicado: (2023)

NGcGM3 Ganglioside: A Privileged Target for Cancer Vaccines
por: Fernandez, Luis E., et al.
Publicado: (2010)

GM(1) Ganglioside Inhibits β‐Amyloid Oligomerization Induced by Sphingomyelin
por: Amaro, Mariana, et al.
Publicado: (2016)

Disease‐modifying effects of ganglioside GM1 in Huntington's disease models
por: Alpaugh, Melanie, et al.
Publicado: (2017)

Ganglioside GM1 Targets Astrocytes to Stimulate Cerebral Energy Metabolism
por: Finsterwald, Charles, et al.
Publicado: (2021)

Ganglioside GM3 Synthase Deficiency in Mouse Models and Human Patients
por: Inamori, Kei-ichiro, et al.
Publicado: (2022)

Intraventricular Sialidase Administration Enhances GM1 Ganglioside Expression and Is Partially Neuroprotective in a Mouse Model of Parkinson’s Disease
por: Schneider, Jay S., et al.
Publicado: (2015)

GM1 Ganglioside Modifies α-Synuclein Toxicity and is Neuroprotective in a Rat α-Synuclein Model of Parkinson’s Disease
por: Schneider, Jay S., et al.
Publicado: (2019)

Ganglioside Metabolism and Parkinson's Disease
por: Forsayeth, John, et al.
Publicado: (2018)

Pre-diagnosing and managing patients with GM1 gangliosidosis and related disorders by the evaluation of GM1 ganglioside content
por: Tonin, Rodolfo, et al.
Publicado: (2019)

Recognition of Freezing of Gait in Parkinson’s Disease Based on Machine Vision
por: Li, Wendan, et al.
Publicado: (2022)

Microglial autophagy in Alzheimer’s disease and Parkinson’s disease
por: Wang, Zhifu, et al.
Publicado: (2023)

The biologic role of ganglioside in neuronal differentiation--effects of GM1 ganglioside on human neuroblastoma SH-SY5Y cells.
por: Lee, M. C., et al.
Publicado: (1994)

The role of microglial autophagy in Parkinson’s disease
por: Zhu, Rui, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_u1mngfj9nrbct7n5528vpue58q